Lack of cardiotoxicity with liposomal doxorubicin in an elderly case of ovarian cancer

Maria Ornella Nicoletto, Martin Donach, Lucia Borgato, Cristina Falci, Lucia Zanin, Giovanni De Masi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Ovarian cancer is typically a disease of elderly women, usually occurring after menopause with a peak incidence in the eighth decade of life. Elderly patients are more likely to suffer the adverse effects of chemotherapy, which may influence successive lines of treatment. We describe the case of an elderly woman with platinum-sensitive ovarian cancer treated with several lines of chemotherapy who developed acute cardiogenic pulmonary edema with her first line of therapy, which included paclitaxel, and her fourth line containing gemcitabine. However, a complete regimen of pegylated liposomal doxorubicin in association with oxaliplatin was well tolerated. Other authors have reported absence of cardiotoxicity with liposomal doxorubicin in their study populations, but no mention was made of patients with a known prior susceptibility to transient heart failure when treated with other chemotherapeutic agents. Our case provides evidence that even in these more difficult-to-treat cases, where cumulative cardiotoxicity may be relatively unpredictable, liposomal doxorubicin does not affect cardiac function.

Original languageEnglish
Pages (from-to)204-206
Number of pages3
JournalTumori
Volume93
Issue number2
Publication statusPublished - Mar 2007

Fingerprint

Ovarian Neoplasms
oxaliplatin
gemcitabine
Drug Therapy
Pulmonary Edema
Menopause
Paclitaxel
Platinum
Heart Failure
Incidence
Therapeutics
Population
liposomal doxorubicin
Cardiotoxicity

Keywords

  • Cardiotoxicity
  • Elderly
  • Liposomal doxorubicin
  • Ovarian cancer

ASJC Scopus subject areas

  • Cancer Research

Cite this

Nicoletto, M. O., Donach, M., Borgato, L., Falci, C., Zanin, L., & De Masi, G. (2007). Lack of cardiotoxicity with liposomal doxorubicin in an elderly case of ovarian cancer. Tumori, 93(2), 204-206.

Lack of cardiotoxicity with liposomal doxorubicin in an elderly case of ovarian cancer. / Nicoletto, Maria Ornella; Donach, Martin; Borgato, Lucia; Falci, Cristina; Zanin, Lucia; De Masi, Giovanni.

In: Tumori, Vol. 93, No. 2, 03.2007, p. 204-206.

Research output: Contribution to journalArticle

Nicoletto, MO, Donach, M, Borgato, L, Falci, C, Zanin, L & De Masi, G 2007, 'Lack of cardiotoxicity with liposomal doxorubicin in an elderly case of ovarian cancer', Tumori, vol. 93, no. 2, pp. 204-206.
Nicoletto, Maria Ornella ; Donach, Martin ; Borgato, Lucia ; Falci, Cristina ; Zanin, Lucia ; De Masi, Giovanni. / Lack of cardiotoxicity with liposomal doxorubicin in an elderly case of ovarian cancer. In: Tumori. 2007 ; Vol. 93, No. 2. pp. 204-206.
@article{74fc095617a848a188054816c1ad32b9,
title = "Lack of cardiotoxicity with liposomal doxorubicin in an elderly case of ovarian cancer",
abstract = "Ovarian cancer is typically a disease of elderly women, usually occurring after menopause with a peak incidence in the eighth decade of life. Elderly patients are more likely to suffer the adverse effects of chemotherapy, which may influence successive lines of treatment. We describe the case of an elderly woman with platinum-sensitive ovarian cancer treated with several lines of chemotherapy who developed acute cardiogenic pulmonary edema with her first line of therapy, which included paclitaxel, and her fourth line containing gemcitabine. However, a complete regimen of pegylated liposomal doxorubicin in association with oxaliplatin was well tolerated. Other authors have reported absence of cardiotoxicity with liposomal doxorubicin in their study populations, but no mention was made of patients with a known prior susceptibility to transient heart failure when treated with other chemotherapeutic agents. Our case provides evidence that even in these more difficult-to-treat cases, where cumulative cardiotoxicity may be relatively unpredictable, liposomal doxorubicin does not affect cardiac function.",
keywords = "Cardiotoxicity, Elderly, Liposomal doxorubicin, Ovarian cancer",
author = "Nicoletto, {Maria Ornella} and Martin Donach and Lucia Borgato and Cristina Falci and Lucia Zanin and {De Masi}, Giovanni",
year = "2007",
month = "3",
language = "English",
volume = "93",
pages = "204--206",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Lack of cardiotoxicity with liposomal doxorubicin in an elderly case of ovarian cancer

AU - Nicoletto, Maria Ornella

AU - Donach, Martin

AU - Borgato, Lucia

AU - Falci, Cristina

AU - Zanin, Lucia

AU - De Masi, Giovanni

PY - 2007/3

Y1 - 2007/3

N2 - Ovarian cancer is typically a disease of elderly women, usually occurring after menopause with a peak incidence in the eighth decade of life. Elderly patients are more likely to suffer the adverse effects of chemotherapy, which may influence successive lines of treatment. We describe the case of an elderly woman with platinum-sensitive ovarian cancer treated with several lines of chemotherapy who developed acute cardiogenic pulmonary edema with her first line of therapy, which included paclitaxel, and her fourth line containing gemcitabine. However, a complete regimen of pegylated liposomal doxorubicin in association with oxaliplatin was well tolerated. Other authors have reported absence of cardiotoxicity with liposomal doxorubicin in their study populations, but no mention was made of patients with a known prior susceptibility to transient heart failure when treated with other chemotherapeutic agents. Our case provides evidence that even in these more difficult-to-treat cases, where cumulative cardiotoxicity may be relatively unpredictable, liposomal doxorubicin does not affect cardiac function.

AB - Ovarian cancer is typically a disease of elderly women, usually occurring after menopause with a peak incidence in the eighth decade of life. Elderly patients are more likely to suffer the adverse effects of chemotherapy, which may influence successive lines of treatment. We describe the case of an elderly woman with platinum-sensitive ovarian cancer treated with several lines of chemotherapy who developed acute cardiogenic pulmonary edema with her first line of therapy, which included paclitaxel, and her fourth line containing gemcitabine. However, a complete regimen of pegylated liposomal doxorubicin in association with oxaliplatin was well tolerated. Other authors have reported absence of cardiotoxicity with liposomal doxorubicin in their study populations, but no mention was made of patients with a known prior susceptibility to transient heart failure when treated with other chemotherapeutic agents. Our case provides evidence that even in these more difficult-to-treat cases, where cumulative cardiotoxicity may be relatively unpredictable, liposomal doxorubicin does not affect cardiac function.

KW - Cardiotoxicity

KW - Elderly

KW - Liposomal doxorubicin

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=34249881071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249881071&partnerID=8YFLogxK

M3 - Article

VL - 93

SP - 204

EP - 206

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 2

ER -